News Release

Review of pharmacologic and immunologic agents in the management of COVID-19

Peer-Reviewed Publication

Compuscript Ltd

The novel coronavirus disease 2019 (COVID-19) is the third coronavirus outbreak in the last two decades. Emerging and re-emerging infections like COVID-19 pose serious challenges of the paucity of information and lack of specific cure or vaccines. This leaves utilisation of existing scientific data on related viral infections and repurposing relevant aetiologic and supportive therapies as the best control approach while novel strategies are developed and trialled. Many promising antiviral agents including lopinavir, ritonavir, remdesivir, umifenovir, darunavir, and oseltamivir have been repurposed and are currently trialled for the care for COVID-19 patients. Adjunct therapies for the management of symptoms and to provide support especially in severe and critically ill patients have also been identified. This review provides an appraisal of the current evidence for the rational use of frontline therapeutics in the management of COVID-19. It also includes updates regarding COVID-19 immunotherapy and vaccine development.

 

Highlights

  • In the absence of a definite treatment, management of COVID-19 depends on rational repurposing of drugs.
  • Choice of pharmacologic agents for use in COVID-19 patients is based on presenting symptoms, severity and underlying conditions.
  • Therapeutics in the management of COVID-19 can be categorised into antiviral drugs, supportive treatments and immunotherapeutic agents.

 

Keywords: SAR-CoV-2, COVID-19, Respiratory, Drug repurposing, Antiviral, Supportive therapy, Immunotherapy

 

# # # # # #

 

Biosafety and Health is sponsored by the Chinese Medical Association, managed by National Institute for Viral

Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC).

For more information, please visit https://www.journals.elsevier.com/biosafety-and-health

Editorial Board: https://www.sciencedirect.com/journal/biosafety-and-health/about/editorial-board

Biosafety and Health is available on ScienceDirect (https://www.sciencedirect.com/journal/biosafety-and-health).

Submissions to Biosafety and Health may be made using Editorial Manager®

(https://www.editorialmanager.com/bsheal/default.aspx).

CiteScore: 4.8

ISSN 2590-0536

 

# # # # # #

 

Marzuq A. Ungogo, Mustapha Mohammed, Bala N. Umar, Auwal A. Bala, Garba M. Khalid, Review of pharmacologic and immunologic agents in the management of COVID-19, Biosafety and Health, Volume 3, Issue 3, 2021, Pages 148-155, ISSN 2590-0536, https://doi.org/10.1016/j.bsheal.2021.01.001


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.